猪肺磷脂注射液联合经鼻持续气道正压通气治疗新生儿呼吸窘迫综合征的临床研究  

Clinical Analysis of Poractant Alfa Injection combined nCPAP for treating neonatal respiratory distress syndrome

作　　者：陈均[1] 陈健[1] 

机构地区：[1]广东省茂名市妇幼保健院新生儿科,525000

出　　处：《临床合理用药杂志》2012年第17期17-18,共2页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的探讨猪肺磷脂注射液(PS)联合经鼻持续气道正压通气(nCPAP)用于新生儿呼吸窘迫综合征(NRDS)的临床疗效。方法将72例NRDS患儿随机分为治疗组40例和对照组32例。在常规治疗基础上,治疗组予以PS联合nCPAP治疗;对照组予以nCPAP呼吸支持治疗。比较2组治疗后12、24h时点血气指标[动脉血氧分压(PaO2)、动脉血二氧化碳分压(PaCO2)、氧合指数(PaO2/FiO2)]及临床转归。结果治疗组治疗后24h时点PaO2、PaO2/FiO2高于12h时点,且高于对照组;治疗后24h时点PaCO2低于12h时点,且低于对照组;病死率为5.0%,低于对照组的50.0%,差异均有统计学意义(P<0.05和P<0.01)。结论 PS联合nCPAP治疗NRDS安全、有效,值得临床推广应用。Objective To explore the curative effect of Poractant Alfa Injection （PS） combined nCPAP for treating neonatal respiratory distress syndrome. Methods The 72 cases with neonatal respiratory distress syndrome who were in our NICU from April 2009 to April 2010,were divided into treatment group （40 cases,treated with PS combined nCPAP ） and control group （ 32 cases, treated with nCPAP）. After the treatment, 12,24b Blood Indexes of arterial partial pressure of oxygen （ PaO2 ） , arterial partial pressure of carbon dioxide （ PaCO2 ） , oxygenation index （ PaO2/FiO2 ） ）and clinical prognosis in the two groups were observed. Results 24h after treatment, the level of PaO2 and PaO2/FiO2 was higher obviously and PaCO2 was lower obviously in 12h and ther improvement was significant in treatment group. The mortality rate in the treatment group was 5% , lower than that of control group （50%）, and the difference was statistically significant（ P 〈 0.05 and P 〈 0. 01 ）. Conclusion PS combined nCPAP is safe and effective,and it is worth spreading clinically.

关 键 词：猪肺磷脂注射液 经鼻持续气道正压通气 新生儿呼吸窘迫综合征 血气指标 

分 类 号：R722.1[医药卫生—儿科]